A class of type 2 diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors may increase the risk of inflammatory bowel disease, according to a new study published in the peer-reviewed medical journal, The BMJ. DPP-4 inhibitors include the brand name type 2 diabetes medications Januvia, Onglyza and Tradjenta. DPP4 inhibitors work to reduce blood sugar levels by blocking the action of DPP-4, an enzyme that destroys the hormone incretin. Incretins help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed. The population-based cohort ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.